Navigation Links
Neodyne Biosciences Announces Issuance of U.S. Patent for Devices and Methods for Dressing Applicators
Date:12/3/2013

MENLO PARK, Calif., Dec. 3, 2013 /PRNewswire/ -- Neodyne Biosciences, a medical device company focused on the development and commercialization of innovative tissue repair devices to promote healing and minimize scar formation, announced today that it has been issued U.S. Patent No. 8,592,640 entitled "Devices and Methods for Dressing Applicators." 

This marks the 7th issued patent in the Neodyne Biosciences portfolio and further supports the company's first product, embrace® Advanced Scar Therapy, which received 510(k) clearance from the US Food and Drug Administration (FDA) in September, 2011. embrace® Advanced Scar Therapy delivers a unique mechanism of action to off-load tension across a newly formed scar, and has been proven to significantly improve scar appearance in a randomized, controlled study.[1]

"Adding another patent to our intellectual property portfolio strengthens our position in the marketplace as we continue to address physician and patient demand for an effective treatment of post-surgical scarring," said Bill Beasley, President of Neodyne Biosciences.

The newly issued patent is owned by Neodyne Biosciences and is accessible on the USPTO's website at www.uspto.gov.

About Neodyne Biosciences, Inc.

Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.

Investor Relations Contacts:

Bill Beasley

President/COO

bbeasley@neodynebio.com

Randy Haden 

Vice President, Sales

rhaden@neodynebio.com

[1] Lim AF, et al. The embrace Device Significantly Decreases Scarring Following Scar Revision Surgery in a Randomized Control Trial. (In press, Plastic and Reconstructive Surgery)


'/>"/>
SOURCE Neodyne Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ARMO BioSciences Initiates Phase 1 Clinical Trial of First-In-Class Cancer Immunotherapy
2. 3-V Biosciences Names Dr. William McCulloch Chief Medical Officer
3. Lilly Statement on Contribution to Indiana Biosciences Research Institute
4. Indiana Biosciences Research Institute Hits $50 Million Start-Up Funding Goal
5. Regado Biosciences, Inc. Adds Global Pharmaceutical Business Veteran to Board of Directors
6. Pressure BioSciences, Inc. Discusses Record Third Quarter Revenue, Strong Fourth Quarter Guidance, Significant Progress on New Instrument Systems, and Expectation to Pay-Off All Outstanding Convertible Notes at the SeeThruEquity Financial Conference
7. Regado Biosciences, Inc. Announces Third Quarter 2013 Results
8. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
9. Sangamo BioSciences Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir In Subjects with Long-Term Infection
10. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
11. Calithera Biosciences Secures $35 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) announced ... operating results on Monday, August 7, 2017 after market ... p.m. ET. Shareholders ... of the conference call by dialing 877-201-0168 or 647-788-4901 ... 15 minutes prior to the call. A live webcast ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017  IBM ... of Alberta in Edmonton, Canada ... journal, Schizophrenia 1 , demonstrating that AI and ... with 74% accuracy. This retrospective analysis also showed ... in schizophrenia patients with significant correlation, based on ...
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, announced ... and divided between two full-time university students enrolled in U.S. or Canadian accredited ... apply for the scholarship, students are asked to submit an essay between 750 ...
(Date:7/24/2017)... ... ... The International Essential Tremor Foundation (IETF) will host a free educational forum in ... take place on Saturday, Aug. 26 at the Embassy Suites by Hilton Cleveland Rockside ... a.m. to 12 p.m., with check-in beginning at 8 a.m. The event is sponsored ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
(Date:7/24/2017)... CA (PRWEB) , ... July 24, 2017 , ... ... financial organizations, today announced it has partnered with WALLIX to expand its ... Publication 800-171 . , There are a number of ways to address the authentication ...
(Date:7/24/2017)... ... July 24, 2017 , ... The Topricin Companies, formerly Topical ... Topricin’s revolutionary, natural, after-burn skin care product, Topricin After Burn Cream. ... term skin conditions, including cancer. In the short term, overexposure to sun, ...
Breaking Medicine News(10 mins):